Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH)

University Hospital, Brest108 enrolled

Overview

This study was a French multicentric cross-sectional study retrospectively of 108 consecutive advanced NSCLC patients with a PD-L1 TPS ≥50% and without EGFR/ALK aberrations treated by pembrolizumab in first line.

Study Type

OBSERVATIONAL

Enrollment

108

Conditions

Carcinoma, Non-Small-Cell Lung Immunotherapy

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * histologically or cytologically confirmed NSCLC PD- L1 TPS ≥ 50% stage III and IV WHO performance status of 0, 1 or 2 adequate organ function Exclusion Criteria: * previous EGFR or ALK aberrations positive test for hepatitis B or C virus indicating acute or chronic infection known history of testing positive for human immunodeficiency virus (HIV) severe, uncontrolled autoimmune disease.

Locations (2)

CHRU de Brest

Brest, France

CHIC de QUIMPER

Quimper, France

Outcomes

Primary Outcomes

progression free survival with pembrolizumab

time from initiation of pembrolizumab to the date of disease progression or death

Time frame: time from initiation of pembrolizumab to the date of disease progression or death ( 20 months)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.